Global Alzheimer's therapeutics market to grow by $5.41b through 2028

It sees advancements with new drug classes like cholinesterase inhibitors.

The global Alzheimer's disease therapeutics market size is projected to expand by $5.41b from 2024-2028 with an estimated compound annual growth rate of 10.03% during the forecast period, according to Technavio.

In its analysis, Technavio said availability, research, and development of novel biomarkers is driving market growth, with a trend towards emergence of regenerative therapies. However, the high cost of therapeutics development poses a challenge.

As Alzheimer's disease remains to be a major health concern, its therapeutics market is seeing advancements in treatment with the introduction of drug classes like cholinesterase inhibitors and Amyloid beta inhibitors. Biological therapies, such as Tau antibody, are also in the pipeline.

Technavio said life expectancy and memory impairment are driving high prescription rates.

Distribution channels, including hospitals, pharmacies, and e-commerce platforms, aim to improve access. Meanwhile, smartphones and the Internet facilitate e-commerce access to essential medications.

Despite these developments, there are still no disease-modifying treatments for the disease. Researchers continue their efforts to find curative therapies, focusing on understanding the underlying mechanisms of neuronal damage and cognitive impairment, Technavio noted.